Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Multiple Myeloma: Executive Summary
2.1 Multiple Myeloma Market Is Expected to Grow to $21.6B in 2027
2.2 Multiple Myeloma Pipeline Is Diverse, Comprising Therapies with Novel Mechanisms of Action
2.3 Opportunities Remain for More Effective and Conveniently Administered Therapies in Multiple Myeloma
2.4 Anti-BCMA Biologics Are Best Equipped to Penetrate the Multiple Myeloma Market
2.5 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 Diagnosed Incidence of MM
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.4.3 Diagnosed Incident Cases of MM
5.4.4 Diagnosed Incident Cases of MM by Symptom Status
5.4.5 Diagnosed Incident Cases of MM by SCT Eligibility
5.4.6 Diagnosed Incident Cases of MM by Chromosomal Abnormalities
5.4.7 Diagnosed Incident Cases of MM by R-ISS Staging
5.4.8 Diagnosed Prevalent Cases of MM
5.5 Epidemiological Forecast for Multiple Myeloma (2017-2027)
5.5.1 Diagnosed Incident Cases of MM
5.5.2 Age-Specific Diagnosed Incident Cases of MM
5.5.3 Sex-Specific Diagnosed Incident Cases of MM
5.5.4 Diagnosed Incident Cases of MM by Symptom Status
5.5.5 Diagnosed Incident Cases of MM by SCT Eligibility
5.5.6 Diagnosed Incident Cases of MM by Chromosomal Abnormalities
5.5.7 Diagnosed Incident Cases of MM by R-ISS Staging
5.5.8 Diagnosed Prevalent Cases of MM
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.2.1 Diagnosis
6.2.2 Clinical Practice
6.3 5EU
6.3.1 France
6.3.2 Germany
6.3.3 Italy
6.3.4 Spain
6.3.5 UK
6.3.6 Japan
6.3.7 China

7 Competitive Assessment
7.1 Overview

8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Improved Treatments for Patients with High-Risk Cytogenetics
8.3 Personalized Approach to Treatment Using Cytogenetic Profiles
8.4 Treatment of Heavily Pretreated Patients
8.5 Improved Route of Administration

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Takeda Portfolio Assessment
10.4 BMS and Celgene Portfolio Assessment
10.5 Amgen Portfolio Assessment
10.6 J&J Portfolio Assessment
10.7 Novartis Portfolio Assessment
10.8 Sanofi Portfolio Assessment
10.9 AbbVie and Roche Portfolio Assessment
10.10 GSK Portfolio Assessment
10.11 Karyopharm Portfolio Assessment

11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 China
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers

12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic/Biosimilar Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research - KOLs Interviewed for This Report
12.4.1 KOLs
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologist
12.6.4 Reviewers
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About the Publisher
12.8 Contact Us
12.9 Disclaimer

List of Tables
Table 1: Multiple Myeloma: Key Metrics in the 8MM
Table 2: Disease Manifestation in Multiple Myeloma
Table 3: DS and ISS Systems and Their Relationships to Disease Stage
Table 4: Risk Factors for MM
Table 5: Treatment Guidelines for Multiple Myeloma
Table 6: Country Profile - US
Table 7: Country Profile - France
Table 8: Country Profile - Germany
Table 9: Country Profile - Italy
Table 10: Country Profile - Spain
Table 11: Country Profile - UK
Table 12: Country Profile - Japan
Table 13: Country Profile - China
Table 14: Leading Treatments for Multiple Myeloma, 2019
Table 15: Takeda's Multiple Myeloma Portfolio Assessment, 2019
Table 16: BMS and Celgene's Multiple Myeloma Portfolio Assessment, 2019
Table 17: Amgen's Multiple Myeloma Portfolio Assessment, 2019
Table 18: J&J's Multiple Myeloma Portfolio Assessment, 2019
Table 19: Novartis' Multiple Myeloma Portfolio Assessment, 2019
Table 20: Sanofi's Multiple Myeloma Portfolio Assessment, 2019
Table 21: AbbVie and Roche's Multiple Myeloma Portfolio Assessment, 2019
Table 22: GSK's Multiple Myeloma Portfolio Assessment, 2019
Table 23: Karyopharm's Multiple Myeloma Portfolio Assessment, 2019
Table 24: Multiple Myeloma Market - Global Drivers and Barriers, 2017-2027
Table 25: Key Events Impacting Sales for Multiple Myeloma in the US, 2017-2027
Table 26: Multiple Myeloma Market - Drivers and Barriers in the US, 2017-2027
Table 27: Key Events Impacting Sales for Multiple Myeloma in the 5EU, 2017-2027
Table 28: Multiple Myeloma Market - Drivers and Barriers in the 5EU, 2017-2027
Table 29: Key Events Impacting Sales for Multiple Myeloma in Japan, 2017-2027
Table 30: Multiple Myeloma Market - Global Drivers and Barriers in Japan, 2017-2027
Table 31: Key Events Impacting Sales for Multiple Myeloma in China, 2017-2027
Table 32: Multiple Myeloma Market - Global Drivers and Barriers in China, 2017-2027
Table 33: Key Historical and Projected Launch Dates for MM
Table 34: Key Historical and Projected Patent Expiry Dates for MM
Table 35: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for Multiple Myeloma in 2017 and 2027
Figure 2: Analysis of the Company Portfolio Gap in Multiple Myeloma During the Forecast Period
Figure 3: Competitive Assessment of the Pipeline Agents that the publisher expects to be Licensed for the Treatment of Multiple Myeloma During the Forecast Period
Figure 4: 8MM, Age-Standardized Diagnosed Incidence of MM (Cases per 100,000 Population), Men, Ages =40 Years, 2007 to 2027
Figure 5: 8MM, Age-Standardized Diagnosed Incidence of MM (Cases per 100,000 Population), Women, Ages =40 Years, 2007 to 2027
Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MM
Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by Symptom Status
Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by SCT Eligibility
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by Chromosomal Abnormalities
Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by R-ISS Staging
Figure 12: 8MM, Diagnosed Incident Cases of MM, Both Sexes, Ages =40 Years, N, 2017
Figure 13: 8MM, Age-Specific Diagnosed Incident Cases of MM, Both Sexes, Ages =40 Years, N, 2017
Figure 14: 8MM, Sex-Specific Diagnosed Incident Cases of MM, Ages =40 Years, N, 2017
Figure 15: 8MM, Diagnosed Incident Cases of MM by Symptom Status, Both Sexes, Ages =40 Years, N, 2017
Figure 16: 8MM, Diagnosed Incident Cases of MM by SCT Eligibility, Both Sexes, Ages =40 Years, N, 2017
Figure 17: 8MM, Diagnosed Incident Cases of MM by Chromosomal Abnormalities, Both Sexes, Ages =40 Years, N, 2017
Figure 18: 8MM, Diagnosed Incident Cases of MM by R-ISS Staging, Both Sexes, Ages =40 Years, N, 2017
Figure 19: 8MM, Diagnosed Prevalent Cases of MM, Both Sexes, Ages =40 Years, N, 2017
Figure 20: Patient Journey for SCT-e and SCT-i NDMM
Figure 21: Patient Journey for RRMM
Figure 22: Unmet Needs and Opportunities in Multiple Myeloma
Figure 23: Overview of the Development Pipeline in Multiple Myeloma
Figure 24: Key Phase I-II-III Trials for the Promising Pipeline Agents That the publisher expects to Be Licensed for Multiple Myeloma in the 8MM During the Forecast Period
Figure 25: Competitive Assessment of the Pipeline Agents That the publisher expects to Be Licensed for the Treatment of Multiple Myeloma During the Forecast Period
Figure 26: Analysis of the Company Portfolio Gap in Multiple Myeloma During the Forecast Period
Figure 27: Global (8MM) Sales Forecast by Country for Multiple Myeloma, 2017 and 2027
Figure 28: Global (8MM) Sales Forecast by Therapy Class for Multiple Myeloma, 2017 and 2027
Figure 29: Sales Forecast by Class for Multiple Myeloma in the US in 2017 and 2027
Figure 30: Sales Forecast by Class for Multiple Myeloma in the 5EU in 2017 and 2027
Figure 31: Sales Forecast by Class for Multiple Myeloma in Japan in 2017 and 2027
Figure 32: Sales Forecast by Class for Multiple Myeloma in China in 2017 and 2027

• AbbVie


• Amgen


• Antengene


• BioLineRx


• Bluebird Bio


• Bristol-Myers Squibb


• Celgene


• Genentech


• Genmab


• GlaxoSmithKline


• F. Hoffmann-La Roche


• Johnson & Johnson


• Juno Therapeutics


• Karyopharm Therapeutics


• Legend Biotech


• Novartis


• Oncopeptides


• Ono


• Regeneron


• Sanofi


• Sellas


• Takeda